Key result
Fetal cardiomyopathy diagnosed in the later era (2013-2019) had a significantly higher rate of confirmed or strongly suspected genetic etiology compared to the earlier era (76% vs 38%; P=0.04).
Why the study?
To examine the impact of advanced genetic testing and improved perinatal management strategies by assessing the rate and type of genetic diagnosis and clinical outcome of fetal cardiomyopathy across two eras.
Does diagnosis and management in a more recent era (2013-2019) compared to an earlier era (2003-2012) improve genetic diagnosis rates and neonatal survival in fetal cardiomyopathy?
Cohort (n=38)
Does diagnosis and management in a more recent era (2013-2019) compared to an earlier era (2003-2012) improve genetic diagnosis rates and neonatal survival in fetal cardiomyopathy?
Absolute Event Rate: 76% vs 38%
p-value: p=0.04
Recent advances in genetic testing have significantly increased the rate of confirmed genetic diagnoses in fetal cardiomyopathy, though improvements in perinatal management have not yet yielded statistically significant increases in neonatal survival.
May increase diagnostic yield in fetal CM with modern testing; leaves open impact on outcomes in this retrospective series.
OBJECTIVE: To assess the rate and type of genetic diagnosis and clinical outcome of cases of fetal cardiomyopathy (CM) during two eras, in order to examine the impact of advanced genetic testing and improved perinatal management strategies. METHODS: All diagnoses of fetal CM in Alberta, Canada, encountered between 2003 and 2019, were reviewed retrospectively. Genetic, cardiac and non-cardiac diagnoses and clinical outcome were documented. Cases with CM secondary to extracardiac pathology and maternal conditions were excluded. Cases diagnosed in the earlier era of the study period (2003-2012) were compared with those diagnosed in the later era (2013-2019). RESULTS: Thirty-eight cases of fetal CM met the inclusion criteria. Median gestational age (GA) at diagnosis was 22.8 (range, 13.4-37.4) weeks. Associated structural heart disease was present in 39% (15/38) of cases and 24% (9/38) had arrhythmia. Hydrops was identified in 29% (11/38) of cases at presentation, and a further 18% (7/38) developed hydrops later in gestation. Twenty-six percent (10/38) of cases underwent termination of pregnancy and 24% (9/38) had intrauterine death. Of liveborn cases, neonatal death occurred in 16% (3/19), late death occurred in 21% (4/19) and 63% (12/19) were alive at the last follow-up. Excluding cases that had termination of pregnancy and those with a liveborn infant who received planned palliative care, the rate of neonatal survival was higher in the later compared with the earlier era (69% (11/16) vs 45% (5/11)), although the difference was not statistically significant (P = 0.26). A genetic etiology was confirmed in 39% (15/38) of cases and strongly suspected in 24% (9/38). A significantly higher proportion of cases had a confirmed or strongly suspected genetic etiology in the later era compared with in the earlier era (76% (19/25) vs 38% (5/13); P = 0.04). CONCLUSIONS: In the recent era, a higher proportion of fetal CM cases had a confirmed or strongly suspected genetic etiology than reported previously. Based on comparison with older series, modern perinatal management strategies may not have a significant impact on neonatal survival in cases of fetal CM; however, a larger study would be better powered to detect more subtle differences.
No takes yet. Share an insight, caveat, or question.
Trakmulkichkarn et al. (2021) conducted a cohort in Fetal cardiomyopathy (n=38). Later era of diagnosis (2013-2019) vs. Earlier era of diagnosis (2003-2012) was evaluated on Confirmed or strongly suspected genetic etiology (p=0.04). Fetal cardiomyopathy diagnosed in the later era (2013-2019) had a significantly higher rate of confirmed or strongly suspected genetic etiology compared to the earlier era (76% vs 38%; P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: